No connection

Search Results

INGN vs KRRO

INGN
Inogen, Inc.
BEARISH
Price
$6.33
Market Cap
$172.4M
Sector
Healthcare
AI Confidence
85%
KRRO
Korro Bio, Inc.
BEARISH
Price
$12.68
Market Cap
$182.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
INGN
--
KRRO
--
Forward P/E
INGN
-20.42
KRRO
-1.67
P/B Ratio
INGN
0.9
KRRO
2.32
P/S Ratio
INGN
0.49
KRRO
28.61
EV/EBITDA
INGN
-7.36
KRRO
-1.82

Profitability

Gross Margin
INGN
44.24%
KRRO
0.0%
Operating Margin
INGN
-12.21%
KRRO
-1229.33%
Profit Margin
INGN
-6.52%
KRRO
0.0%
ROE
INGN
-12.43%
KRRO
-110.7%
ROA
INGN
-6.35%
KRRO
-32.14%

Growth

Revenue Growth
INGN
2.0%
KRRO
-43.1%
Earnings Growth
INGN
--
KRRO
--

Financial Health

Debt/Equity
INGN
0.09
KRRO
0.85
Current Ratio
INGN
3.12
KRRO
6.9
Quick Ratio
INGN
2.52
KRRO
6.38

Dividends

Dividend Yield
INGN
--
KRRO
--
Payout Ratio
INGN
0.0%
KRRO
0.0%

AI Verdict

INGN BEARISH

INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.

Strengths
Very low leverage (Debt/Equity 0.09)
Strong short-term liquidity (Current Ratio 3.12)
Healthy Gross Margin (44.24%)
Risks
Critical operational failure (Piotroski F-Score 1/9)
Stagnant top-line growth (YoY Revenue Growth 2.00%)
Persistent net losses and negative ROE (-12.43%)
KRRO BEARISH

KRRO exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company maintains a strong liquidity position with a current ratio of 6.90, this is offset by an extreme operating margin of -1229.33% and negative revenue growth of -43.10%. The stock is in a heavy technical downtrend, having lost over 70% of its value in the last six months. Despite a bullish analyst target of $20.00, the deterministic data suggests a high-risk speculative profile with no current path to profitability.

Strengths
Strong short-term liquidity (Current Ratio: 6.90)
Recent trend of beating EPS estimates (2/4 last quarters)
Significant upside gap to analyst target price ($20.00)
Risks
Extreme cash burn reflected in -1229.33% operating margin
Severe revenue contraction (-43.10% YoY)
Critical fundamental health (Piotroski F-Score: 1/9)

Compare Another Pair

INGN vs KRRO: Head-to-Head Comparison

This page compares Inogen, Inc. (INGN) and Korro Bio, Inc. (KRRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile